English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18055/20253 (89%)
Visitors : 24604127      Online Users : 501
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34693


    標題: No survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancer
    作者: Kang, Nai-Wen
    Kuo, Yu-Hsuan
    Wu, Hung-Chang
    Ho, Chung-Han
    Chen, Yi-Chen
    Yang, Ching-Chieh
    貢獻者: Chi Mei Hospital
    Chia Nan University of Pharmacy & Science
    Chia Nan University of Pharmacy & Science
    Chi Mei Hospital
    Southern Taiwan University of Science & Technology
    Chi Mei Hospital
    Chia Nan University of Pharmacy & Science
    關鍵字: concurrent chemoradiotherapy
    mucoepidermoid carcinoma
    neck-cancer
    head
    radiotherapy
    management
    cisplatin
    outcomes
    tumors
    日期: 2022
    上傳時間: 2023-12-11 14:05:28 (UTC+8)
    出版者: NATURE PORTFOLIO
    摘要: This study aimed to compare survival of patients with advanced major salivary gland cancers treated with adjuvant chemoradiation therapy (CRT) versus radiotherapy (RT) alone, after surgical resection. The Taiwan Cancer Registry database was used to identify patients (2009-2017) with advanced (T3-4 or nodal positivity) major salivary gland cancers, treated post-surgically with adjuvant CRT or RT alone. Overall survival (OS) and disease-specific survival (DSS) evaluated using Kaplan-Meier. Stratified analyses conducted on clinicopathological features. A total of 395 patients were analyzed: 178 (45.1%) received adjuvant CRT; 217 (54.9%) received adjuvant RT alone. Median radiation dose was 66 Gy in 33 fractions. Cisplatin was most common chemotherapy regimen. After a median follow-up of 3.37 years, there was no significant difference in OS or DSS (p=0.1354 and 0.3361, respectively) between groups. Adding chemotherapy to adjuvant RT was not significantly associated with improved OS (adjusted hazard ratio [aHR] 0.94; 95% CI 0.72-1.23) and DSS (aHR 0.96; 95% CI 0.72-1.28). Stratified analysis of clinicopathological features found no significant advantages for improved OS or DSS from adding chemotherapy to adjuvant RT. Thus, in this population database, the use of chemotherapy provided limited survival benefits in advanced major salivary gland cancers after surgical resection.
    關聯: SCIENTIFIC REPORTS, v.12, n.CB2, pp.CC2, pp.-,
    Appears in Collections:[行政單位] 123

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML87View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback